Last reviewed · How we verify
Methotrexate+Prednisone
Methotrexate inhibits dihydrofolate reductase to suppress cell proliferation and immune activation, while prednisone suppresses inflammatory and immune responses through glucocorticoid receptor binding.
Methotrexate inhibits dihydrofolate reductase to suppress cell proliferation and immune activation, while prednisone suppresses inflammatory and immune responses through glucocorticoid receptor binding. Used for Rheumatoid arthritis, Systemic lupus erythematosus, Vasculitis.
At a glance
| Generic name | Methotrexate+Prednisone |
|---|---|
| Sponsor | University of Parma |
| Drug class | Antimetabolite + Corticosteroid combination |
| Target | Dihydrofolate reductase (methotrexate); Glucocorticoid receptor (prednisone) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
This combination leverages methotrexate's antimetabolite and immunosuppressive properties—particularly effective in rheumatologic conditions—paired with prednisone's broad anti-inflammatory and immunosuppressive effects via glucocorticoid signaling. Together they reduce both cellular proliferation and inflammatory cytokine production, making the combination useful in autoimmune and inflammatory diseases.
Approved indications
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Vasculitis
- Other autoimmune inflammatory conditions
Common side effects
- Bone marrow suppression
- Infection
- Gastrointestinal toxicity
- Hepatotoxicity
- Immunosuppression-related complications
- Corticosteroid-related side effects (hyperglycemia, osteoporosis, mood changes)
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia (PHASE2)
- Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL (NA)
- Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methotrexate+Prednisone CI brief — competitive landscape report
- Methotrexate+Prednisone updates RSS · CI watch RSS
- University of Parma portfolio CI